<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4131</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> http://dx.doi.org/10.31782/IJCRR.2021.131919</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Comparative Efficacy and Tolerability of Luliconazole versus Terbinafin in Pediatric Patients-A Randomized Trial&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Harinkhere Sanjay</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Arya Raj</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anubhav</surname><given-names>Garg</given-names></name></contrib><contrib contrib-type="author"><name><surname>P.</surname><given-names>Ranjan K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saroj</surname><given-names>Kothari</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>11</day><month>10</month><year>2021</year></pub-date><volume>9)</volume><issue/><fpage>17</fpage><lpage>22</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Aim/Objective: Luliconazole is a newer imidazole antifungal drug effective against a variety of fungal infections, especially dermatophytosis, which is one of the most common superficial fungal infections, caused by dermatophytes. The present study is designed to compare the efficacy and tolerability of topical antifungal drug luliconazole with terbinafine used for the treatment of a variety of fungal infections, especially dermatophytosis. Materials and Method: In this perspective, the observational and open level study randomly selected patients (those fulfilling the inclusion criteria) are categorized according to diagnosis and had been advised to apply topically the respective drug during the study period. Results: In the present study we found that the luliconazole was more efficacious and tolerable than terbinafine at a short term therapy. Conclusion: Luliconazole was better efficacious and tolerable than terbinafine in relieving signs and symptoms of dermatophytosis, especially pruritus and desquamation.&#13;
</p></abstract><kwd-group><kwd>Dermatophytosis</kwd><kwd> Efficacy</kwd><kwd> Pruritus</kwd><kwd> Tolerable</kwd><kwd> Dermatophytes</kwd><kwd> Desquamation</kwd></kwd-group></article-meta></front></article>
